Highlights Pyxis Oncology, Inc.

Equities

PYXS

US7473241013

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
3.31 ^USD	+3.12%		-1.78%	+83.89%

06-10	Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of Directors	CI
05-14	Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M	05-14	MT
Health Care Up on Drug Sales Optimism -- Health Care Roundup	03-21	DJ
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Pyxis Oncology Completes Acquisition of Apexigen	23/08/23	MT
Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	22/08/23	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs	30/05/23	CI
Pyxis Oncology to Acquire Apexigen in $16 Million All-Stock Deal	24/05/23	MT
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Pyxis Oncology Reprices Stock Options Issued Prior to Initial Public Offering -- Shares Jump Premarket	29/03/23	MT
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	22/03/23	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	22/03/23	CI
Pyxis Oncology, Inc. Announces Dosing of First Subject in Phase 1 Trial of Pyx-201, A Novel ADC for Solid Tumors	16/03/23	CI
Powell Comments Slightly Lift Exchange-Traded Funds, Stock Futures Premarket Thursday	01/12/22	MT
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	01/11/22	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Pyxis Oncology Secures Exclusive License To Biosion's BSI-060T Product Candidate	29/03/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pyxis Oncology, Inc.

Equities

PYXS

US7473241013

Highlights

Filters